Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Fovea Gilead Sciences |
---|---|
Information provided by: | Fovea |
ClinicalTrials.gov Identifier: | NCT00697944 |
To assess the safety of Ambisome 10 mg/kg/week in patients as a preemptive treatment in intensive care patients with a sepsis and rising candida colonisation.
Preemptive treatment (i.e., prophylactic treatment with two high doses of Ambisome® administered with an interval of one week, in patiens with a high risk of developing a fungal infection) should decrease the incidence of actual systemic infections.
The incidence of such actual fungal infections will be assessed directly and its impact on patients' survival and intensive care resourches assessed
Condition | Intervention | Phase |
---|---|---|
Sepsis Candida |
Drug: Amphotericine in liposome (Ambisome®) |
Phase IV |
Study Type: | Interventional |
Study Design: | Prevention, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Ambisome® Preemptive Treatment of Multiple Colonizations by Candida in Intensive Care Patients With a Sepsis |
Estimated Enrollment: | 30 |
Study Start Date: | March 2008 |
Estimated Study Completion Date: | March 2009 |
Estimated Primary Completion Date: | February 2009 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Patients with neutropenia of that underwent a bone marrow tar organ transplant or with cancer chemotherapy
Contact: Jean−François RI DREYFUS, MD PhD | 33-61-282-6780 | jfdreyfus@aol.com |
France | |
Hopital Saint Louis | Not yet recruiting |
PARIS, France, 75010 | |
Chu Michallon | Recruiting |
GRENOBLE, France, 38000 | |
Contact: TIMSIT jftimsit@chu-grenoble.fr |
Principal Investigator: | Elie AZOULAY, MD PhD | University Teaching Hospital Saint Louis, Paris |
Responsible Party: | FOVEA ( DREYFUS Medical director ) |
Study ID Numbers: | AMBIDEX, EUDRA−CT 2007−004444−71 |
Study First Received: | June 12, 2008 |
Last Updated: | June 13, 2008 |
ClinicalTrials.gov Identifier: | NCT00697944 |
Health Authority: | France: Institutional Ethical Committee |
FUNGAL INFECTION SEPSIS INTENSIVE CARE |
AMBISOME PREEMPTIVE TREATMENT Sepsis with candida colonisation |
Abelcet Systemic Inflammatory Response Syndrome Amphotericin B Mycoses Sepsis Clotrimazole |
Miconazole Tioconazole Liposomal amphotericin B Torulopsis Inflammation |
Anti-Bacterial Agents Anti-Infective Agents Antiparasitic Agents Antiprotozoal Agents Pathologic Processes Antifungal Agents |
Therapeutic Uses Antibiotics, Antifungal Amebicides Infection Pharmacologic Actions |